A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2030

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: Mirabegron
DRUG: Placebo

Sponsor

Astellas Pharma Inc